Foreign Institutional Investors (FIIs) are significant players in global financial markets, comprising various entities such as mutual funds, pension funds, and hedge funds, among others. They invest substantial capital across international borders, influencing market dynamics, liquidity, and investment trends, thus playing a crucial role in shaping global investment landscapes and economic development.
Here are stocks in which FII increased their stake up to 2.42 % in Q4FY24 from Q3FY24
APL Apollo Tubes Ltd
APL Apollo Tubes Limited is in the business of producing electric resistance welded (ERW) steel tubes. Its product options include approximately 1,100 different types of pre-galvanized tubes, structural steel tubes, galvanized tubes, MS black dipes, and hollow sections.
With a market capitalization of Rs 42,903.91 crore, on Tuesday, the shares closed at Rs 1,545.95 per share, decreasing around 0.18 percent as compared to the previous closing price.
The foreign institutional investors of the company increased their stake by 1.44%, from 29.25% in Q3FY24 to 30.69% in Q4FY24. Additionally, 25.81% is owned by retail investors, 14.06% is held by domestic institutional investors, and 29.44% is owned by promoters. The company’s revenue stood at Rs 4,178 crore in Q3FY24, during the same time frame, net profit stood at Rs 166 crore.
EIH Ltd
EIH Limited is an Indian premium hospitality firm. The company’s primary business is to own and manage luxury hotels and cruises under the Oberoi and Trident brands. The company is also involved in flight catering, airport eateries, project management, and corporate air charters.
With a market capitalization of Rs 29,285.80 crore, on Tuesday,the shares closed at Rs 468.30 per share, increasing around 1.25 percent as compared to the previous closing price.
The foreign institutional investors of the company increased their stake by 1.54%, from 3.71% in Q3FY24 to 5.25% in Q4FY24. Additionally, 48.13% is owned by retail investors, 13.77% is held by domestic institutional investors, and 32.85% is owned by promoters. The company’s revenue stood at Rs 741 crore in Q3FY24, during the same time frame, net profit stood at Rs 230 crore.
Natco Pharma Ltd
Natco Pharma Limited is an India-based vertically integrated pharmaceutical firm that focuses on research and development (R&D). The company is in the pharmaceutical business, which includes research and development, manufacturing, and marketing bulk medications as well as final dosage formulation.
With a market capitalization of Rs 17,808.89 crore, on Tuesday, the shares were closed at Rs 994.30 per share, increasing around 1.24 percent as compared to the previous closing price.
The foreign institutional investors of the company increased their stake by 2.42%, from 13.72% in Q3FY24 to 16.14% in Q4FY24. Additionally, 24.46% is owned by retail investors, 9.69% is held by domestic institutional investors, and 49.71% is owned by promoters. The company’s revenue stood at Rs 759 crore in Q3FY24, during the same time frame, net profit stood at Rs 213 crore.
Written by:- Abhishek Singh
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
